Tag: Senza
High-frequency SCS drives impactful outcomes for non-surgical refractory back pain patients
Following the recent introduction of key data supporting the use of high-frequency spinal cord stimulation (SCS) in the treatment of non-surgical refractory back pain...
Nevro announces clinical data reinforcing significant and durable benefits of 10kHz...
Nevro Corporation has announced the results from data presentations at the 25th North American Neuromodulation Society (NANS) annual meeting (13–15 January 2022; Orlando, USA) supporting...
Nevro announces three key data publications on novel painful diabetic neuropathy...
Nevro has announced three clinical data publications on treating painful diabetic neuropathy (PDN) with 10kHz spinal cord stimulation (SCS) therapy—including 12-month data from the...
High-frequency SCS takes the stage to relieve chronic pain from diabetic...
Following the recent approval of the Senza system (Nevro) by the US Food and Drug Administration (FDA), Erika A Petersen (Little Rock, USA) discusses the...
Nevro announces FDA approval of 10kHz high-frequency SCS therapy for painful...
Nevro has announced receipt of US Food and Drug Administration (FDA) approval for its Senza system for the treatment of chronic pain associated with...
Nevro receives TGA approval for Senza II spinal cord stimulation system...
The Therapeutic Goods Administration (TGA) has granted approval to Nevro for its next-generation Senza II spinal cord stimulation system delivering the company’s proprietary HF10...
Nevro receives CE mark for full-body MRI conditional labelling with the...
Nevro has received the CE mark for full-body magnetic resonance imaging (MRI) conditional labelling on the Senza Spinal Cord Stimulation (SCS) System delivering HF10...
Nevro files lawsuit for patent infringement against Boston Scientific in the...
Nevro Corp has announced that it has filed a lawsuit for patent infringement against units of Boston Scientific. The lawsuit, filed in the United States...
Blue Cross Blue Shield denies coverage for high-frequency spinal cord stimulation...
Blue Cross Blue Shield has denied coverage for high frequency spinal cord stimulation in at least two states. Outposts of the federation of...
